Indicators
Indicators
Value
Direction
MACD(12,26,9)
1.449
Neutral
RSI(14)
49.627
Neutral
STOCH(KDJ)(9,3,3)
64.936
Neutral
ATR(14)
2.961
Low Volatility
CCI(14)
43.561
Neutral
Williams %R
35.882
Buy
TRIX(12,20)
-0.046
Sell
StochRSI(14)
0.000
Sell
CRISPR Therapeutics AG
CRSP56.250USD
-0.430-0.76%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
5.28BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of CRISPR Therapeutics AG
Currency: USD Updated: 2025-12-15Key Insights
CRISPR Therapeutics AG's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 77/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 78.43.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CRISPR Therapeutics AG's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
30
analysts
Buy
Current Rating
78.427
Target Price
+36.73%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CRISPR Therapeutics AG Highlights
StrengthsRisks
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 3014.69% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 37.31M.
Fairly Valued
The company’s latest PE is -10.15, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 79.52M shares, increasing 0.09% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 10.68K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-15The current financial score of CRISPR Therapeutics AG is 6.26, ranking 285/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 889.00K, representing a year-over-year increase of 47.67%, while its net profit experienced a year-over-year increase of 23.85%.
Score
Financials
6.73
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.41
Operational Efficiency
2.85
Growth Potential
7.21
Shareholder Returns
7.10
CRISPR Therapeutics AG's Company Valuation
Currency: USD Updated: 2025-12-15The current valuation score of CRISPR Therapeutics AG is 6.72, ranking 241/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -10.15, which is -100.00% below the recent high of 0.00 and -352.89% above the recent low of -45.96.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 77/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-15The current earnings forecast score of CRISPR Therapeutics AG is 7.53, ranking 282/404 in the Biotechnology & Medical Research industry. The average price target for CRISPR Therapeutics AG is 74.50, with a high of 268.00 and a low of 32.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
30
analysts
Buy
Current Rating
78.427
Target Price
+36.73%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
BeOne Medicines AG
ONC
24
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-15The current price momentum score of CRISPR Therapeutics AG is 8.95, ranking 81/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 61.34 and the support level at 49.59, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
57.130
Sell
MA10
56.564
Sell
MA20
54.422
Buy
MA50
60.380
Sell
MA100
59.158
Sell
MA200
50.855
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-15The current institutional shareholding score of CRISPR Therapeutics AG is 7.00, ranking 85/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 84.90%, representing a quarter-over-quarter decrease of 5.23%. The largest institutional shareholder is Catherine Wood, holding a total of 9.79M shares, representing 10.27% of shares outstanding, with 12.75% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Capital International Investors
Orbis Investment Management Ltd.
State Street Investment Management (US)
T. Rowe Price Investment Management, Inc.
UBS Financial Services, Inc.
Amova Asset Management Co., Ltd.
Amova Asset Management Americas, Inc
1
2
Risk Assessment
Currency: USD Updated: 2025-12-15The current risk assessment score of CRISPR Therapeutics AG is 5.16, ranking 59/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.68. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.68
VaR
+5.70%
240-Day Maximum Drawdown
+41.02%
240-Day Volatility
+65.59%
Return
Best Daily Return
60 days
+10.07%
120 days
+18.22%
5 years
+18.22%
Worst Daily Return
60 days
-8.97%
120 days
-8.97%
5 years
-13.32%
Sharpe Ratio
60 days
-0.46
120 days
+0.91
5 years
+0.05
Risk Assessment
Maximum Drawdown
240 days
+41.02%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+1.11
3 years
+0.02
5 years
-0.10
Skewness
240 days
+0.88
3 years
+0.86
5 years
+0.58
Volatility
Realised Volatility
240 days
+65.59%
5 years
--
Standardised True Range
240 days
+5.23%
5 years
+6.67%
Downside Risk-Adjusted Return
120 days
+174.02%
240 days
+174.02%
Maximum Daily Upside Volatility
60 days
+46.02%
Maximum Daily Downside Volatility
60 days
+38.55%
Liquidity
Average Turnover Rate
60 days
+3.82%
120 days
+3.10%
5 years
--
Turnover Deviation
20 days
-100.00%
60 days
-100.00%
120 days
-100.00%
Peer Comparison
Biotechnology & Medical Research
CRISPR Therapeutics AG
CRSP
7.09 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of CRISPR Therapeutics AG?
The TradingKey Stock Score provides a comprehensive assessment of CRISPR Therapeutics AG based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of CRISPR Therapeutics AG’s performance and outlook.
How do we generate the financial health score of CRISPR Therapeutics AG?
To generate the financial health score of CRISPR Therapeutics AG, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects CRISPR Therapeutics AG's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of CRISPR Therapeutics AG.
How do we generate the company valuation score of CRISPR Therapeutics AG?
To generate the company valuation score of CRISPR Therapeutics AG, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare CRISPR Therapeutics AG’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of CRISPR Therapeutics AG’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of CRISPR Therapeutics AG.
How do we generate the earnings forecast score of CRISPR Therapeutics AG?
To calculate the earnings forecast score of CRISPR Therapeutics AG, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on CRISPR Therapeutics AG’s future.
How do we generate the price momentum score of CRISPR Therapeutics AG?
When generating the price momentum score for CRISPR Therapeutics AG, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of CRISPR Therapeutics AG’s prices. A higher score indicates a more stable short-term price trend for CRISPR Therapeutics AG.
How do we generate the institutional confidence score of CRISPR Therapeutics AG?
To generate the institutional confidence score of CRISPR Therapeutics AG, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about CRISPR Therapeutics AG’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of CRISPR Therapeutics AG.
How do we generate the risk management score of CRISPR Therapeutics AG?
To assess the risk management score of CRISPR Therapeutics AG, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of CRISPR Therapeutics AG’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of CRISPR Therapeutics AG.
